Published in Cancer Chemother Pharmacol on September 13, 2008
Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion. J Control Release (2013) 0.93
A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs (2010) 0.83
Lifespan based indirect response models. J Pharmacokinet Pharmacodyn (2012) 0.81
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Invest New Drugs (2010) 0.80
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity. Cancer Immunol Immunother (2010) 0.79
Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther (2009) 0.75
Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother (2014) 0.75
Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur J Clin Pharmacol (2016) 0.75
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2012) 8.00
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med (2007) 7.05
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
The incidences and mortalities of major cancers in China, 2009. Chin J Cancer (2013) 5.17
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol (2012) 3.75
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34
[Trend analysis and projection of cancer incidence in China between 1989 and 2008]. Zhonghua Zhong Liu Za Zhi (2012) 3.15
[Trend analysis of cancer mortality in China between 1989 and 2008]. Zhonghua Zhong Liu Za Zhi (2012) 3.10
Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res (2013) 2.88
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol (2010) 2.61
Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol (2004) 2.58
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 2.34
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer (2011) 2.23
Microarray-based gene expression profiles in multiple tissues of the domesticated silkworm, Bombyx mori. Genome Biol (2007) 2.21
Fibrocystin/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function. J Am Soc Nephrol (2008) 2.04
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol (2009) 1.99
Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos (2003) 1.93
Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis (2011) 1.81
Highly efficient and specific genome editing in silkworm using custom TALENs. PLoS One (2012) 1.80
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol (2013) 1.79
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol (2009) 1.78
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab (2010) 1.72
Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J Pharmacol Exp Ther (2003) 1.71
Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol (2004) 1.65
Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One (2008) 1.64
Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist (2007) 1.61
Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res (2008) 1.60
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol (2009) 1.60
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res (2010) 1.57
Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev (2009) 1.57
Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leuk Lymphoma (2010) 1.55
Enhanced serodiagnostic utility of novel Mycobacterium tuberculosis polyproteins. J Infect (2012) 1.52
Predicting drug-drug interactions: an FDA perspective. AAPS J (2009) 1.52
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer (2011) 1.51
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
Cancer incidence and mortality in china, 2006. Chin J Cancer Res (2011) 1.50
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer (2004) 1.49
Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res (2012) 1.49
The odorant binding protein gene family from the genome of silkworm, Bombyx mori. BMC Genomics (2009) 1.48
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res (2004) 1.47
MicroRNAs of Bombyx mori identified by Solexa sequencing. BMC Genomics (2010) 1.46
The clinical approach toward giant cell tumor of bone. Oncologist (2014) 1.46
Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol (2004) 1.45
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother (2010) 1.44
Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet (2008) 1.44
RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol (2009) 1.44
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Will the dark sky over advanced renal cell carcinoma soon become brighter? Eur J Cancer (2005) 1.43
Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet (2011) 1.42
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist (2008) 1.41
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer (2011) 1.41
Dealing with the complex drug-drug interactions: towards mechanistic models. Biopharm Drug Dispos (2015) 1.40
Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn (2002) 1.40
The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res (2004) 1.40
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2006) 1.40
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci (2013) 1.38
Adsorption of 2-mercaptobenzothiazole from aqueous solution by organo-bentonite. J Environ Sci (China) (2013) 1.38
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Pharmacodynamics and pharmacogenomics of methylprednisolone during 7-day infusions in rats. J Pharmacol Exp Ther (2002) 1.36
Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res (2009) 1.35
Retracted MicroRNA expression profiling during the life cycle of the silkworm (Bombyx mori). BMC Genomics (2009) 1.35
Volume of preclinical xenograft tumors is more accurately assessed by ultrasound imaging than manual caliper measurements. J Ultrasound Med (2010) 1.35
Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis (2009) 1.35
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos (2006) 1.33
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat (2014) 1.32
Characterization and expression patterns of let-7 microRNA in the silkworm (Bombyx mori). BMC Dev Biol (2007) 1.32
Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther (2003) 1.31
Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res (2005) 1.29
Human papillomavirus infection and sporadic breast carcinoma risk: a meta-analysis. Breast Cancer Res Treat (2010) 1.28
A gamma-glutamyl transpeptidase-independent pathway of glutathione catabolism to glutamate via 5-oxoproline in Arabidopsis. Plant Physiol (2008) 1.27
Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models. Theranostics (2012) 1.27
Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer (2010) 1.27
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol (2007) 1.27
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.26
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 1.26
Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration. Clin Pharmacokinet (2015) 1.26
Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene (2005) 1.25
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res (2011) 1.24
[An analysis of lung cancer mortality in China, 2004 - 2005]. Zhonghua Yu Fang Yi Xue Za Zhi (2010) 1.24
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs (2014) 1.24
Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res (2009) 1.24
Cocirculation and evolution of two lineages of influenza B viruses in europe and Israel in the 2001-2002 season. J Clin Microbiol (2003) 1.24
KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res (2005) 1.24
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol (2008) 1.23
Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck (2006) 1.23
Identification and expression pattern of the chemosensory protein gene family in the silkworm, Bombyx mori. Insect Biochem Mol Biol (2006) 1.22
Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist (2011) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21